Dr. Raheem Chaudhry
Psychiatry is still the part of medicine that diagnoses by impression rather than measurement. I'm working to change that by bringing objective, scalable signals like speech into how serious mental illness is detected and treated.
My focus is US community behavioural health: the services that see the most serious illness and are given the least to work with.
Co-founder and COO of Psyrin, building on the speech-biomarker research I contributed to and the analysis pipeline I designed. A former NHS doctor, I trained in medicine at King's College London and worked in liaison psychiatry.
What I'm working on
Serious mental illness affects millions of Americans, and it is most often missed where clinical capacity is thinnest: in the community behavioural-health services that carry the heaviest caseloads with the fewest clinicians, the least support and training, and, too often, no psychiatrist at all. My work is to make mental-health assessment objective and scalable, and to get that technology working in exactly those settings.
What's deployed today is Mira, Psyrin's conversational clinical AI, built with strict clinical guardrails. She is live across multi-site US community behavioural-health organisations, with consistently strong feedback from the patients and staff who use her. Behind her sits the research: turning speech into a measurable clinical signal, validated in peer-reviewed work and now moving through clinical trials.
At a glance
Company. Co-founder & COO of Psyrin, VC-backed across two funding rounds and supported by UK Research and Innovation. Working with the State of Ohio — including the July 2026 launch of RecoveryRachel with RecoveryOhio — and clinics across America.
Peer-reviewed research. Detecting schizophrenia, bipolar disorder, psychosis vulnerability and major depressive disorder from 5 minutes of online-collected speech. Translational Psychiatry, 2025.
Patent. Vocal Assessment: UK patent GB2635194A, assessing mental characteristics from speech; assignee Psyrin Ltd; published May 2025.
Clinical trial. Principal Investigator on MINDAIM (NCT06792175), a prospective US study of speech-based machine-learning assessment in community behavioural health, with partner organisations in Ohio and Massachusetts.
Deployment. Leading the rollout of Mira, Psyrin’s conversational clinical AI, across multi-site community behavioural-health organisations in the United States, including clinician and staff training.
Peer-reviewed research on detecting serious mental illness from speech.
Deploying clinical AI in community behavioural health.
Equality in health, primary care, access, and research.
Full chronology and recognition.